替莫唑胺治疗侵袭性垂体腺瘤与垂体癌的德国调查
该德国回顾性调查纳入47例侵袭性垂体腺瘤(34例)或垂体癌(13例)患者,多数采用标准方案中位6个周期替莫唑胺治疗。中位随访32个月后,肿瘤退缩9例(20%)、稳定8例(17%)、进展29例(63%),中位无进展生存期23个月,长期结局欠佳。
要点
- 替莫唑胺治疗侵袭性垂体瘤早期缓解率可观,但长期肿瘤进展率高达63%。
- 中位无进展生存期为23个月,进展多发生在治疗启动后16个月。
- 侵袭性垂体腺瘤与垂体癌的疾病稳定率和无进展生存期无差异。
核心结论
- 替莫唑胺治疗侵袭性垂体腺瘤或垂体癌的早期缓解率令人鼓舞,但长期结局欠佳。
- 应考虑延长替莫唑胺给药时间。
- 未能证实既往报道的肿瘤对替莫唑胺反应的预测因素。
研究设计与样本
- 德国全国性回顾性调查,纳入47例侵袭性垂体腺瘤(n=34)或垂体癌(n=13)患者,其中女性22例。
- 诊断时平均年龄45±15岁;免疫组化亚型为促肾上腺皮质激素型(n=20)、催乳素型(n=18)和无功能型(n=9)。
- 替莫唑胺多在初诊后8年启动,多数患者采用标准方案,中位6个周期。
主要发现
- 中位随访32个月时,4例仍在替莫唑胺治疗;46例有结局数据者中肿瘤退缩9例(20%)、稳定8例(17%)、进展29例(63%)。
- 肿瘤进展发生在替莫唑胺启动后16个月,中位估计无进展生存期为23个月。
- 侵袭性垂体腺瘤与垂体癌患者的疾病稳定率和中位无进展生存期无差异。
- 未识别出肿瘤反应的预测因素,替莫唑胺总体耐受良好。
临床怎么用
- 对侵袭性垂体腺瘤或垂体癌可考虑替莫唑胺治疗,但需关注长期进展风险。
- 治疗中应延长替莫唑胺给药并密切随访影像学,因进展多发生于启动后16个月左右。
局限性
- 为回顾性调查设计,结局数据仅46例可评估。
- 未能识别肿瘤对替莫唑胺反应的预测因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Despite growing evidence that temozolomide (TMZ) therapy is effective for the treatment of aggressive pituitary tumors (APTs) or carcinomas (PCs), individual therapy decisions remain challenging. OBJECTIVE: We therefore aimed to report on clinical characteristics leading to initiation of TMZ therapy and to add evidence on TMZ long-term effectiveness. DESIGN AND SUBJECTS: Retrospective survey on TMZ treatment in patients with APTs or PCs. TMZ therapy was initiated in 47 patients (22 females) with APTs (n = 34) or PCs (n = 13). Mean age at diagnosis was 45 ± 15 years. The immunohistochemical subtypes were corticotroph (n = 20), lactotroph (n = 18), and nonfunctioning (n = 9) tumors. TMZ therapy started 8 years after initial diagnosis using a standard regimen (median 6 cycles) for the majority of patients. RESULTS: Long-term radiological response to TMZ after a median follow-up of 32 months with 4 patients still on TMZ therapy was tumor regression for 9 (20%), stable disease for 8 (17%), and tumor progression for 29 patients (63%) (outcome data available for 46 patients). Progression occurred 16 months after initiation of TMZ. Median estimated progression-free survival was 23 months. Disease stabilization and median progression-free survival did not differ between patients with APTs or PCs. Predictors of tumor response were not identified. Overall, TMZ was well tolerated. CONCLUSION: We performed a nationwide survey on TMZ therapy in patients with APTs and PCs. While early response rates to TMZ are promising, long-term outcome is less favorable. Prolonged TMZ administration should be considered. We were not able to confirm previously reported predictors of tumor response to TMZ.
引用
- Elbelt U, Schlaffer SM, Buchfelder M, et al. Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey. J Clin Endocrinol Metab. 2020. PMID: 31746334. doi:10.1210/clinem/dgz211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。